Pfizer shows profit growth from cost cuts and steadier COVID sales
Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as it aims to show investors steadier execution and growth after large swings related to its COVID-19 vaccine.
Pfizer CEO 'Cautiously Optimistic'
In mid-2024, the commercial president of Pfizer’s oncology unit Suneet Varma announced his retirement after 15 years with the ...
The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow ...
A Huntsville-based biotechnology company has secured $10 million in funding to begin the trial of a new way to deliver medication to advanced Parkinson’s disease patients.
(Reuters) -Drugmaker Pfizer beat Wall Street estimates for fourth-quarter profit on Thursday, boosted by cost-cutting, a ...
Pfizer reported strong 2024 profits Wednesday on the same day the Connecticut Attorney General’s office released a statement ...
Pfizer has ended development of a B7-H4-directed antibody-drug conjugate (ADC), triggering a $1 billion impairment charge. | ...
Pfizer's fourth quarter beat expectations on strong sales of its Covid vaccine and pill, bolstering its sales as it seeks to ...
Pfizer (PFE) stock is up today after the pharmaceutical company reported earnings for the fourth quarter of 2024. The company ...
Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See ...
2don MSN
CEO Albert Bourla says Pfizer has met the strategic goals it had set for itself in 2024, and that it was ‘executing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback